Figure 5.

αCD22 Ab-MXD3 ASO conjugate shows significant in vivo therapeutic efficacy in two human patient-derived leukemia mouse models. Kaplan-Meier survival curves for mice inoculated with two patient-derived leukemia cells (A and B). The mice were treated with PBS, free αCD22 Ab (1 mg/kg) plus free MXD3 ASO (0.8 mg/kg), and two different doses of the αCD22 Ab-MXD3 ASO conjugate (0.2 mg/kg or 1 mg/kg of the Ab). (A) PBS versus conjugate at both doses (***p < 0.001). Conjugate 0.2 mg/kg versus 1 mg/kg (of the Ab) (***p < 0.001). (n = 8). (B) PBS versus conjugate at both doses (**p < 0.01). Conjugate 0.2 mg/kg versus 1 mg/kg (of the Ab) (**p < 0.01). (n = 6)